- A first-of-its-kind clinical trial in the United States is investigating the efficacy of a nasal vaccination for the treatment of Alzheimer’s disease.
- The first stage of the test will last around six months, followed by a year-long second trial involving 150 patients.
In the United States, a first-of-its-kind clinical trial explores the efficacy of a nasal vaccine for treating Alzheimer’s disease.
The study, undertaken at Brigham and Women’s Hospital in Boston, is the first human trial of a nasal vaccine for the condition and will begin enrolling volunteers this week.
The Co-director of the Ann Romney Center for Neurologic Diseases at the Brigham, Dr. Howard Weiner, who will lead the studies, said in a statement, “If clinical trials in humans prove that the vaccine is safe and effective, this could represent a nontoxic treatment for people with Alzheimer’s, and it could also be given early to help prevent Alzheimer’s in people at risk.”
Protollin, an immunotherapy medicine that boosts the body’s immune system and targets a build-up of beta-amyloid protein plaques in the brain, will be tested in the vaccination. Scientists believe that these build-ups are one of the reasons that human brain cells in Alzheimer’s disease are unable to function normally.
According to a hospital press statement, the phase one experiment will include 16 patients between the ages of 60 and 85 who have early symptomatic Alzheimer’s disease but are otherwise healthy. Protollin will be given to them in two doses, one week apart.
Protollin is safe in other vaccinations. However, according to Weiner’s pre-trial studies, a nasally delivered dose produces the best benefits and has no notable side effects.
The vaccine, according to Weiner, “can help with the disease and, more crucially, it can be given to people who are in danger for the disease or who already have it and are unaware of it.”
He claims that many persons in their 50s and 60s, despite having normal cognition, exhibit symptoms of Alzheimer’s disease on brain imaging.
According to the hospital’s announcement, the experiment will be used to determine “the vaccine’s safety and tolerability.” Researchers will also measure white blood cell counts to see how the vaccine affects individuals’ immunological responses.
The first stage of the test will last around six months, followed by a year-long second trial involving 150 patients.
Alzheimer’s disease is a type of dementia that causes a person’s memory, thinking, and behaviour to deteriorate. These cognitive problems eventually worsen to the point that they impede daily work. It is the advanced cause of dementia, accounting for 60 to 80 per cent of all cases.
According to the Alzheimer’s Association, more than 747,000 Canadians have Alzheimer’s disease or another form of dementia.
Scientists haven’t been able to pinpoint the exact causes of Alzheimer’s disease, according to the National Institute on Aging (NIA), but believe it is caused by a combination of genetic, environmental, and lifestyle factors.
Source: Global News
Get Canada and Manitoba’s top News, Market news, and other worldwide news only on Manitoba Daily.